Mark Pruzanski Sells 705 Shares of Intercept Pharmaceuticals Inc. (ICPT) Stock
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) CEO Mark Pruzanski sold 705 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $163.20, for a total value of $115,056.00. Following the completion of the transaction, the chief executive officer now directly owns 552,020 shares in the company, valued at $90,089,664. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Mark Pruzanski also recently made the following trade(s):
- On Tuesday, September 20th, Mark Pruzanski sold 35,000 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $165.00, for a total value of $5,775,000.00.
Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) opened at 153.51 on Friday. The company’s 50 day moving average price is $158.07 and its 200-day moving average price is $150.46. Intercept Pharmaceuticals Inc. has a 52 week low of $89.76 and a 52 week high of $217.99. The firm’s market capitalization is $3.80 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) EPS for the quarter, topping analysts’ consensus estimates of ($3.69) by $0.55. The company had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $1.72 million. Intercept Pharmaceuticals had a negative net margin of 5,003.95% and a negative return on equity of 50.58%. Intercept Pharmaceuticals’s revenue was up 1140.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.99) EPS. On average, equities research analysts expect that Intercept Pharmaceuticals Inc. will post ($16.31) EPS for the current fiscal year.
A number of analysts have issued reports on ICPT shares. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 28th. Laidlaw lowered Intercept Pharmaceuticals from a “buy” rating to a “sell” rating and lowered their target price for the company from $345.00 to $105.00 in a report on Friday, August 5th. Wedbush reaffirmed an “outperform” rating and issued a $239.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, June 24th. Robert W. Baird reaffirmed an “outperform” rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a report on Thursday, September 22nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $218.00 target price (down previously from $219.00) on shares of Intercept Pharmaceuticals in a report on Friday, August 5th. Five equities research analysts have rated the stock with a sell rating, five have given a hold rating and ten have assigned a buy rating to the company. Intercept Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $177.67.
Several large investors have recently bought and sold shares of the company. CENTRAL TRUST Co bought a new stake in Intercept Pharmaceuticals during the second quarter worth approximately $107,000. Legal & General Group Plc boosted its stake in Intercept Pharmaceuticals by 15.8% in the first quarter. Legal & General Group Plc now owns 1,144 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 156 shares during the period. Metropolitan Life Insurance Co. NY boosted its stake in Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 38 shares during the period. Pacer Advisors Inc. bought a new stake in Intercept Pharmaceuticals during the second quarter worth approximately $180,000. Finally, IBM Retirement Fund boosted its stake in Intercept Pharmaceuticals by 3.6% in the second quarter. IBM Retirement Fund now owns 1,657 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 58 shares during the period. 81.86% of the stock is currently owned by institutional investors.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.